Short answer: Very little. As of October 2026, the published human data on BPC-157 is three small studies with no control group (30 people in total) plus one trial in ulcerative colitis that only exists as a 2005 meeting abstract. FDA told its compounding advisers in July 2026 that this was not enough to judge whether BPC-157 works, and that it found no human pharmacokinetic data for injected, oral, nasal or skin use. Almost everything you read about BPC-157 healing tendons comes from rats.
BPC-157 is one of the most talked-about peptides online. It is a 15-amino-acid fragment first described in 1993, and it is often sold as a "healing peptide" for tendons, joints and the gut. We already have a longer guide to its pharmacology and regulatory history. This article asks a narrower question: what has actually been tested in people, and what did it show?
To answer it, we read every human study we could find on PubMed, three recent systematic reviews, and the 2026 FDA briefing document written for the Pharmacy Compounding Advisory Committee (PCAC). Here is what is there.
A systematic review published in October 2026 searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to June 1, 2026. It found three studies with a total of 30 people that met its criteria. It judged all three to be of poor quality and rated the overall certainty of evidence as "very low" (Poolton 2026). Two earlier reviews reached the same picture: a 2025 narrative review counted only three pilot studies in humans (McGuire 2025), and a 2025 systematic review of 36 BPC-157 studies found that 35 were preclinical and just one was clinical (Vasireddi 2025).
FDA's own literature search, described in its briefing document, turned up five clinical reports in total once meeting abstracts on rectal (enema) use were included. None of them was a full, peer-reviewed randomized trial.
The most-cited human study is a chart review from a single clinic in Florida (Lee and Padgett 2021). The authors looked back at 17 patients who had received a BPC-157 injection into the knee, sometimes combined with thymosin beta-4, and reached 16 of them by phone 6 to 12 months later. Patients were asked to recall their pain before the shot and how much it helped.
There was no control group, no blinding and no imaging. People with many different causes of knee pain were grouped together. Pain often improves on its own, and recall months later is unreliable. This study can tell you that some patients felt better. It cannot tell you that BPC-157 caused it.
The second study is a retrospective pilot in 12 people with interstitial cystitis (painful bladder syndrome), who had BPC-157 placed directly into the bladder. The 2026 systematic review lists it alongside the other two and reports that, as in the others, most participants described symptom improvement without treatment-related side effects, again with no control group (Poolton 2026).
The third study tested whether BPC-157 given into a vein causes obvious harm (Lee and Burgess 2025). It enrolled two adults, a 58-year-old man and a 68-year-old woman, who had both had IV BPC-157 before. They received 10 mg on day 1 and 20 mg on day 2, each in 250 mL of saline over an hour. Blood tests for the heart, liver, kidneys, thyroid and blood sugar did not change, and neither reported side effects.
Two people over two days cannot establish safety. It can only show that nothing dramatic happened in those two people in that window. The authors themselves say more studies are needed.
The closest thing to a real trial is a randomized, double-blind, placebo-controlled study of a BPC-157 enema (code name PL 14736) in ulcerative colitis, reported at a meeting in 2005. FDA's 2026 briefing describes it this way:
FDA concluded that, because the details were missing, these data were "inadequate to support the efficacy and safety" of a two-week BPC-157 enema for ulcerative colitis. It also noted that blood levels of BPC-157 were not detected after rectal dosing in the studies that measured them.
On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee met to discuss whether BPC-157 (both the free base and the acetate salt) should go on the list of bulk substances that state-licensed pharmacies may use to compound drugs under section 503A. The original nominations had been withdrawn, but FDA chose to evaluate both forms on its own. It looked at BPC-157 for ulcerative colitis only, because the nominations did not include enough information to evaluate other uses such as tendinitis, and it found no clinical studies in those groups.
The briefing document's key points on human evidence:
Trade press (RAPS) reported that the committee nevertheless voted 8 to 6, with one abstention, to recommend adding BPC-157 for ulcerative colitis. As of October 22, 2026, FDA's meeting page did not yet list official minutes, and no final rule has been published. A committee vote is advice. FDA makes the decision, through rulemaking. Our explainer on the 2026 compounding decisions covers the process.
There are dozens of rat studies showing faster healing of tendons, muscle, bone and gut lining. Those results are why people are interested. But many drugs that work in rodents fail in people, and none of the human studies above was designed to show that BPC-157 heals anything. The reviews agree: the 2025 systematic review called the human data level IV and V evidence, and the 2026 review concluded BPC-157 "should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials."
BPC-157 is named on the World Anti-Doping Agency's 2026 Prohibited List under S0, "non-approved substances", which are banned at all times. Tested athletes should treat it as banned.
We do not recommend doses, and no human trial has established one. If you and your clinician decide to use BPC-157, careful records are the only way to learn anything from your own experience: what you took, from which vial, when, where you injected, and how you felt before and after. Dose Track lets you log each shot, track the vial and its reconstitution date, and note symptoms, so you can show your clinician a clear history instead of a guess. For storage after mixing, see how long reconstituted peptides last.
Questions about the app? See the help center or join the Dose Track community.
Every number in this article comes from one of these sources, checked on October 22, 2026. This article is for education. It is not medical or legal advice, and nothing here is a dose recommendation.